Ann Rheum Dis 63:324-325 doi:10.1136/ard.2003.008060
  • Letter

Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology

  1. P P Geusens1,
  2. R N J de Nijs2,
  3. W F Lems3,
  4. R F J M Laan4,
  5. A Struijs5,
  6. T P van Staa6,
  7. J W J Bijlsma2
  1. 1Academisch Ziekenhuis Maastricht, The Netherlands and Limburgs Universitair Centrum, Diepenbeek, Belgium
  2. 2Universitair Medisch Centrum Utrecht, The Netherlands
  3. 3Vrije Universiteit Medisch Centrum en Slotervaartziekenhuis, Amsterdam, The Netherlands
  4. 4Academisch Ziekenhuis Nijmegen, The Netherlands
  5. 5Erasmus Medical Centre Rotterdam, The Netherlands
  6. 6Procter and Gamble, UK
  1. Correspondence to:
    Professor P Geusens
    Department of Rheumatology University Hospital Maastricht, 6202 AZ Maastricht, The Netherlands;
  • Accepted 19 May 2003

Haugeberg et al recently published clinical decision rules to identify patients with rheumatoid arthritis (RA) at risk for osteoporosis.1 Included were patients treated with glucocorticoids, a subject that has been for a long time the interest of rheumatologists.2–4

For example, the Dutch Society for Rheumatology has recently published guidelines for the prevention of glucocorticoid induced osteoporosis (GIOP).5 This document was prepared by a group of rheumatologists of the society and other experts to mark the occasion of the publication of the 3rd Osteoporosis Guideline, (the “CBO consensus”) which was, in turn, prepared at the request of the Dutch authorities by a multidisciplinary group who examined evidence based medicine.6

Figure 1 is a stream diagram showing …